Daan van Well - 02 Apr 2026 Form 4/A - Amendment Insider Report for SOPHiA GENETICS SA (SOPH)

Reporting relationship: Chief Legal Officer
Issuer ticker: SOPH
Reported as of: 02 Apr 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 08 Apr 2026, 08:47:32 UTC
Original report date: 03 Apr 2026
Prior SEC filing: 20 Mar 2026
Next SEC filing: 08 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well

Key filing fact

Daan van Well filed Form 4/A - Amendment for SOPHiA GENETICS SA (SOPH) on 08 Apr 2026.

Key facts

This page summarizes Daan van Well's Form 4/A - Amendment filing for SOPHiA GENETICS SA (SOPH).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Apr 2026, 08:47.

Change

Previous filing in this sequence was filed on 20 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0002006414 Primary reporting owner

Van Well Daan

Relationship: Chief Legal Officer
Address: C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND
Signature: /s/ Elimara Brunetto as Attorney-in-Fact for Daan van Well
Signature date: 08 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SOPH transaction

Ordinary Shares

Award

Transaction value
Shares: +97,536
Change %: +37%
Price: $0.000000^*
Shares after: 358,774
Date: 02 Apr 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOPH transaction Derivative

Share Option (Right to Buy)

Award

Transaction value
Shares: +142,216
Change %
Price: $0.000000^*
Shares after: 142,216
Date: 02 Apr 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 142,216
Exercise price: $5.04
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

Footnote F2

This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 97,536 ordinary shares due to an inadvertent error. The correct amount is 358,774 ordinary shares.

Footnote F3

The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.